Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer

Oncology Nursing Forum

Volumn 34, Issue 1, 2007, Pages 55-61

  Limburg, Connie E ^a  

^a San Diego Pacific Oncology and Hematology Association Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BONE DENSITY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HUMAN; LIFESTYLE; MASS SCREENING; MIDDLE AGED; NURSING; OSTEOPOROSIS; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; HUMANS; LIFE STYLE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS;

EID: 34250363686     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/07.ONF.55-63     Document Type: Review

References (36)

1. American Cancer Society. (2006). Breast cancer facts and figures 2005-2006. Retrieved December 5, 2006, from http://www.cancer.org/downloads/STT/ CAFF2005BrF.pdf
2. Bines, J., Oleske, D., & Cobleigh, M. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 14, 1718-1729.
3. Breastcancer.org. (2006). Tamoxifen. Retrieved December 5, 2006, from http://www.breastcancer.org/tre_sys_tamox_idx.html
4. Cann, C., Martin, M., Genant, H., & Jaffe, R. (1984). Decreased spinal mineral content in amenorrheic women. JAMA, 251, 626-629.
5. Chen, Z., Maricic, M., Bassford, T., Pettinger, M., Ritenbaugh, C., Lopez, A., et al. (2005). Fracture risk among breast cancer survivors: Results from the Women's Health Initiative Observational Study. Archives of Internal Medicine, 165, 552-558.
6. Coleman, R. (2004). Hormone- and chemotherapy-induced bone loss in breast cancer. Oncology, 18(Suppl. 5), 16-20.
7. Coombes, R., Hall, E., Gibson, L., Paridaens, R., Jassem, J., Delozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081-1092.
8. Daniel, H., Dunn, S., Ferguson, D., Lomas, G., Niazi, Z., & Stratte, P. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. Journal of Urology, 163, 181-186.
9. Daniell, H.W. (1997). Osteoporosis after orchiectomy for prostate cancer. Journal of Urology, 157, 439-444.
10. Gross, G., Ott, C., Lindsey, A., Twiss, J., & Waltman, N. (2002). Postmenopausal breast cancer survivors at risk for osteoporosis: Physical activity, vigor, and vitality. Oncology Nursing Forum, 29, 1295-1300.
11. Hawkins, B., Campos, M., & Fessele, K. (2005). Got bones? It takes more than milk to preserve skeletal health in oncology patients. Pittsburgh, PA: Oncology Nursing Society.
12. Hillner, B., Ingle, J., Chlebowski, R., Gralow, J., Yee, G., Janjan, N., et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology, 21, 4042-4057.
13. International Osteoporosis Foundation. (2002). Osteoporosis in the workplace. The social, economic, and human costs of osteoporosis on employees, employers, and government. Liege, Belgium: Author.
14. Kanis, J. (2002). Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359, 1929-1936.
15. Kowalak, J.P., Cavallini, M., Chohan, N.D., Hughes, A.S., Johnson, P.H., Poeggel, J.C. (Eds). (2001). Handbook of pathophysiology. Springhouse, PA: Springhouse Corporation.
16. Maillefert, J., Sibilia, J., Michel, F., Saussine, C., Javier, R., & Tavernier, C. (1999). Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. Journal of Urology, 161, 1219-1222.
17. Maxwell, C., & Viale, P. (2005). Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncology Nursing Forum, 32, 589-603.
18. Merck & Co., Inc. (2006). Breast cancer. Retrieved April 30, 2006, from http://www.merck.com/mmpe/sec18/ch253/ch253e.html#sec18-ch253-ch253e-514
19. Mincey, B., Moraghan, T., & Perez, E. (2000). Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic Proceedings, 75, 821-829.
20. National Cancer Institute. (2004). Aromatase inhibitors. Retrieved June 26, 2005, from http://www.cancer.gov/clinicaltrials/developments/aromatase- inhibitors-digest
21. National Institute of Arthritis. (2005). What breast cancer survivors need to know about osteoporosis. Retrieved December 6, 2006, from http://www.niams.nih.gov/bone/hi/osteoporosis_breastcancer.htm
22. National Institutes of Health, (n.d.). NIH osteoporosis and related bone diseases - National Resource Center. Retrieved June 27, 2005, from http://www.niams.nih.gov/bone
23. National Institutes of Health. (2000, October 4). More from the osteoporosis consensus. Retrieved June 20, 2005, from http://jraworld. arthritisinsight.com/feature/osteoporosis/more.html
24. National Institutes of Health. (2006). Osteoporosis overview. Retrieved December 5, 2006, from http://www.niams.nih.gov/bone/hi/overview.htm
25. National Osteoporosis Foundation. (2006). Prevention. Retrieved June 26, 2005, from http://www.nof.org/prevention/calcium.htm
26. Otto, S.E. (2001). Oncology nursing (4th ed.). St. Louis, MO: Mosby.
27. Perry, C., & Figgitt, D. (2004). Zoledronic acid: A review of its use in patients with advanced cancer. Drugs, 64, 1197-1211.
28. Pfeilschifter, J., & Diel, I. (2000). Osteoporosis due to cancer treatment: Pathogenesis and management. Journal of Clinical Oncology, 18, 1570-1593.
29. Powles, T., Hickish, T., Kanis, J., Tidy, A., & Ashley, S. (1996). Effect of tamoxifen on bone mineral density measured by dual-engery x-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology, 14, 78-84.
30. Ramaswamy, B., & Shapiro, C. (2003). Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology, 30, 763-775.
31. Ravdin, P. (2004). Managing the risk of osteoporosis in women with a history of early breast cancer. Oncology, 18, 1385-1390, 1393.
32. Rosen, L. (2004). New generation of Bisphosphonates: Broad clinical utility in breast and prostate cancer. Oncology, 18(Suppl. 5), 26-32.
33. Ross, R., & Small, E. (2002). Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. Journal of Urology, 167, 1952-1956.
34. Saarto, T., Blomqvist, C., Valimaki, M., Sarna, S., & Elomaa, I. (1997). Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. Journal of Clinical Oncology, 15, 1341-1347.
35. Shapiro, C., Manola, J., & Leboff, M. (2001). Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of Clinical Oncology, 19, 3303-3305.
36. U.S. Department of Health and Human Services. (2004). Bone health and osteoporosis: A report of the surgeon general. Retrieved June 21, 2005, from http://www.surgeongeneral.gov/library/bonehealth/content.html